ReviewNature reviews. Cancer2005
Urothelial tumorigenesis: a tale of divergent pathways.
Review in Nature reviews. Cancer, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 314 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
314 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Diagnostic and Prognostic Roles of GATA3 Immunohistochemistry in Urothelial Carcinoma.Medicina (Kaunas, Lithuania) · 2023Pooled it
- Pooled it
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma withClinical cancer research : an official journal of the American Association for Cancer Research · 2017Trial
- Steroid receptor coactivator-3 regulates glucose metabolism in bladder cancer cells through coactivation of hypoxia inducible factor 1α.The Journal of biological chemistry · 2014Trial
- Federated Learning-Based Multi-Task Framework for Privacy-Preserving Diagnosis of Muscle Invasion in Bladder Cancer.Journal of imaging informatics in medicine · 2026Article
- Whole exome sequencing identifies somatically mutated genes in bladder cancer: A pilot study from Bangladesh.Biochemistry and biophysics reports · 2026Article
- Emerging Molecular and Computational Biomarkers in Urothelial Carcinoma: Innovations in Diagnosis, Prognosis, and Therapeutic Response Prediction.Journal of personalized medicine · 2026Review
- Exon-6 truncated p53 Suppresses Innate Immune Responses to Facilitate Immune Evasion in Bladder Cancer.International journal of biological sciences · 2026Article
- Prophylactic role of artemisinin in modulating FGFR3, HRAS, and TP53 to prevent early-stage urothelial carcinoma in BBN-induced mouse models.BMC biotechnology · 2025Article
- The association between PSCA gene polymorphism and hepatocellular carcinoma risk.World journal of surgical oncology · 2025Article
- Genomic subtypes of non-muscle-invasive bladder cancer: guiding immunotherapy decision-making for patients exposed to aristolochic acid.Molecular medicine (Cambridge, Mass.) · 2025Article
- Association of rs2294008 (PSCA) Gene polymorphism in Urothelial Bladder Cancer of South Indian Population.Asian Pacific journal of cancer prevention : APJCP · 2025Article
- An unfolded protein response (UPR)-signature regulated by the NFKB-miR-29b/c axis fosters tumor aggressiveness and poor survival in bladder cancer.Frontiers in molecular biosciences · 2025Article
- CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.PloS one · 2025Article
- Loss of NUMB drives aggressive bladder cancer via a RHOA/ROCK/YAP signaling axis.Nature communications · 2024Article
- Bladder cancer: non-coding RNAs and exosomal non-coding RNAs.Functional & integrative genomics · 2024Review
- Article
- [Histomolecular classification of urothelial carcinoma of the urinary bladder : From histological phenotype to genotype and back].Pathologie (Heidelberg, Germany) · 2024Article
- Article
- Transcriptional signature of CD56Frontiers in immunology · 2024Article
254 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinoma of the bladder is unique among epithelial carcinomas in its divergent pathways of tumorigenesis. Low-grade papillary tumours rarely become muscle-invasive and they frequently harbour gene mutations that constitutively activate the receptor tyrosine kinase-Ras pathway. By contrast, most high-grade invasive tumours progress to life-threatening metastases and have defects in the p53 and the retinoblastoma protein pathways. Correcting pathway-specific defects represents an attractive strategy for the molecular therapy of urothelial carcinomas.
Indexed as
Identifiers
16110317What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.